The Effect of Eplerenone on the Evolution of Vasculopathy in Renal Transplant Patients.
Recruiting
Phase 3
Interventional Study
Kidney Transplantation for More Than One Year
Patients with a Kidney Transplantation on Cyclosporine
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Pivotal Trial
This treatment is in the last trial phase before FDA approval.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 50 and older
- Sex
- Any
- Trial phase
- Phase 3
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 36 (estimated)
- Sponsor
- Central Hospital, Nancy, France · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Cardiovascular (CV) pathologies are the leading cause of death in kidney transplant patients.Arterial stiffness is a prognostic factor for CV mortality in kidney transplantation. Despite a reduced CV risk in transplant kidney patients in comparison to patients in dialysis, CV mortality among kidney transplant patients is much higher than the general population.
After renal transplantation, the ca…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Men or women ≥ 50 years of age;
* Patient who had a kidney transplant at least one year prior to inclusion;
* Patient on cyclosporine;
* Patient whose clinical-biological state has been stable for at least 3 months: no change in treatment with an impact on blood pressure (excl…
Contacts